Literature DB >> 20530286

Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Eynav Klechevsky1, Anne-Laure Flamar, Yanying Cao, Jean-Philippe Blanck, Maochang Liu, Amy O'Bar, Olivier Agouna-Deciat, Peter Klucar, Luann Thompson-Snipes, Sandra Zurawski, Yoram Reiter, A Karolina Palucka, Gerard Zurawski, Jacques Banchereau.   

Abstract

We evaluated human CD8(+) T-cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. We found the immunoreceptor tyrosine-based inhibitory motif-containing DC immunoreceptor (DCIR) to mediate potent cross-presentation. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8(+) T-cell immunity by all human DC subsets including ex vivo-generated DCs, skin-isolated Langerhans cells, and blood myeloid DCs and plasmacytoid DCs. The delivery of influenza matrix protein (FluMP) through DCIR resulted in expansion of FluMP-specific memory CD8(+) T cells. Enhanced specific CD8(+) T-cell responses were observed when an antigen was delivered to the DCs via DCIR, compared with those induced by a free antigen, or antigen conjugated to a control monoclonal antibody or delivered via DC-SIGN, another lectin receptor. DCIR targeting also induced primary CD8(+) T-cell responses against self (MART-1) and viral (HIV gag) antigens. Addition of Toll-like receptor (TLR) 7/8 agonist enhanced DCIR-mediated cross-presentation as well as cross-priming, particularly when combined with a CD40 signal. TLR7/8 activation was associated with increased expansion of the primed CD8(+) T cells, high production of interferon-γ and tumor necrosis factor-α, and reduced levels of type 2-associated cytokines. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8(+) T-cell immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530286      PMCID: PMC2947393          DOI: 10.1182/blood-2010-01-264960

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Inducing and expanding regulatory T cell populations by foreign antigen.

Authors:  Karsten Kretschmer; Irina Apostolou; Daniel Hawiger; Khashayarsha Khazaie; Michel C Nussenzweig; Harald von Boehmer
Journal:  Nat Immunol       Date:  2005-10-23       Impact factor: 25.606

Review 2.  Dendritic cell subsets in health and disease.

Authors:  Hideki Ueno; Eynav Klechevsky; Rimpei Morita; Caroline Aspord; Tinghua Cao; Toshimichi Matsui; Tiziana Di Pucchio; John Connolly; Joseph W Fay; Virginia Pascual; A Karolina Palucka; Jacques Banchereau
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

3.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

Authors:  Tiziana Di Pucchio; Bithi Chatterjee; Anna Smed-Sörensen; Sandra Clayton; Adam Palazzo; Monica Montes; Yaming Xue; Ira Mellman; Jacques Banchereau; John E Connolly
Journal:  Nat Immunol       Date:  2008-03-30       Impact factor: 25.606

Review 4.  T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.

Authors:  Roy Noy; Malka Eppel; Maya Haus-Cohen; Einav Klechevsky; Orian Mekler; Yaeil Michaeli; Galit Denkberg; Yoram Reiter
Journal:  Expert Rev Anticancer Ther       Date:  2005-06       Impact factor: 4.512

5.  APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif.

Authors:  E E Bates; N Fournier; E Garcia; J Valladeau; I Durand; J J Pin; S M Zurawski; S Patel; J S Abrams; S Lebecque; P Garrone; S Saeland
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

6.  Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells.

Authors:  Gersende Caron; Dorothée Duluc; Isabelle Frémaux; Pascale Jeannin; Catherine David; Hugues Gascan; Yves Delneste
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

7.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

8.  Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.

Authors:  Yves Delneste; Giovanni Magistrelli; Jean Gauchat; Jean Haeuw; Jean Aubry; Kayo Nakamura; Naoko Kawakami-Honda; Liliane Goetsch; Tatsuya Sawamura; Jean Bonnefoy; Pascale Jeannin
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction.

Authors:  A Dzionek; Y Sohma; J Nagafune; M Cella; M Colonna; F Facchetti; G Günther; I Johnston; A Lanzavecchia; T Nagasaka; T Okada; W Vermi; G Winkels; T Yamamoto; M Zysk; Y Yamaguchi; J Schmitz
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  106 in total

Review 1.  Targeting human dendritic cell subsets for improved vaccines.

Authors:  Hideki Ueno; Eynav Klechevsky; Nathalie Schmitt; Ling Ni; Anne-Laure Flamar; Sandra Zurawski; Gerard Zurawski; Karolina Palucka; Jacques Banchereau; Sangkon Oh
Journal:  Semin Immunol       Date:  2011-01-28       Impact factor: 11.130

Review 2.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

Review 3.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

4.  Langerin, the "Catcher in the Rye": an important receptor for pathogens on Langerhans cells.

Authors:  Patrizia Stoitzner; Nikolaus Romani
Journal:  Eur J Immunol       Date:  2011-09       Impact factor: 5.532

Review 5.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

Review 6.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

7.  Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.

Authors:  Laurent Gorvel; Daniel Korenfeld; Thomas Tung; Eynav Klechevsky
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

Review 8.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

Review 9.  Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.

Authors:  Jardin Leleux; Alexandra Atalis; Krishnendu Roy
Journal:  J Control Release       Date:  2015-10-20       Impact factor: 9.776

10.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.